So, what’s new with the flu this year?
We’ll get to all the 2026-2027 flu vaccine info you need, but first — let’s dive into a little history. Influenza, or the flu, was named for an epidemic in 15th-century Italy attributed to the “influence of the stars.”
The pandemic of “Spanish” influenza in 1918-1919 caused an estimated 21 million deaths worldwide. Thankfully, scientists in the 1930s succeeded in isolating influenza A and B viruses. This led to the development of inactivated vaccines (IIV) in the late 1930s and 1940s.
Since then, scientists developed the first live attenuated influenza vaccine (LAIV) in 2003, and a non-live recombinant vaccine (RIV) — not requiring growth in hen’s eggs — was licensed in 2013. This year adds another first to that list, which we’ll get to below.
But while the flu may be a household name at this point, it’s important to remember that thousands of people still die yearly from the flu, and many more are hospitalized. Last season made that point emphatically.
In This Article
- What’s new with the flu vaccine this year
- What last season taught us
- Current clinical guidelines
- What flu vaccines are available
- Who should and shouldn’t get vaccinated
- Best timing, side effects, and efficacy
PLEASE NOTE: We research and reference this information, but also express opinions of the experienced professionals of Village Apothecary. We are pharmacists, but we may not be YOUR pharmacist. Do not make any medical decisions without first contacting your primary care provider.
What’s New with the Flu Vaccine This Year?
Here’s the skinny on the 2026-2027 updates:
All three strains were updated. Both influenza A components (H1N1 and H3N2) and the B component are new compared to last season. That’s not routine — often only one or two change. More on why below.
Vaccines remain trivalent. Two A strains and one B strain. The B/Yamagata lineage hasn’t been detected in circulation anywhere since March 2020, so it’s no longer included in anyone’s vaccine.
The first mRNA flu vaccine is here. mFLUSIVA (Moderna) is FDA-approved for adults 50 and older — full approval for ages 50-64, and accelerated approval for 65+ with a confirmatory study still underway. It’s egg-free, contains no preservatives or antibiotics, and Moderna’s data showed stronger antibody responses than high-dose flu vaccine in adults 65+. Availability may be limited to select locations this season while distribution and insurance coverage get worked out.
Egg allergy still isn’t a barrier. Additional safety measures are not recommended for flu vaccination of people with egg allergy, regardless of the severity of previous reactions. That’s been true since the 2023-24 season and remains true now.
Thimerosal, updated. Last year we told you a CDC advisory panel had recommended that all flu vaccines be single-dose and thimerosal-free, and that this was contentious. Here’s where it landed: HHS adopted that recommendation in 2025, then a federal court stayed the underlying committee votes in March 2026 over how the panel had been appointed. In practice it made little difference — U.S. flu vaccine supply had already converted almost entirely to single-dose, thimerosal-free product. The AAP’s objection at the time still reads well: banning vaccine ingredients without solid scientific reasons sets a precedent that doesn’t serve patients.
The flu/COVID combo shot still isn’t here. Moderna’s mRNA-1083 combination vaccine has had a winding path — the original application was withdrawn in 2025, and FDA has requested additional data. It has been approved in Europe (as mCOMBRIAX) but is not available in the U.S. If it arrives, it won’t be this season.
Learn More: Vaccine Ingredients in 2026: Less Scary Than You Might Think
What Last Season Taught Us
This is worth a section of its own, because it explains why this year’s vaccine changed as much as it did — and why we’re being a bit more insistent than usual.
The 2025-2026 season was dominated by an H3N2 variant called subclade K, which emerged fast and was genetically drifted from the strain in that season’s vaccine. Translation: the vaccine was aimed at a slightly different target than the one that showed up.
The result was a hard season. Cumulative hospitalization rates hit the highest level observed since 2010-2011.
But here’s the part that actually matters for your decision. Even against a drifted strain, the vaccine worked. Real-world data from England found effectiveness against flu-related emergency department visits and hospital admissions of 32-39% in adults and 72-75% in children and teens. European studies across 19 countries put all-age effectiveness at 25-45%. Canadian data showed meaningful protection despite substantial mismatch. Lab work at Penn found that the vaccine still elicited antibodies in many people that recognized subclade K.
Those numbers are within the normal range for a flu vaccine in a typical year — during a season the vaccine wasn’t well matched to.
That’s the single best argument we can make for getting your shot. A mismatched flu vaccine still kept people out of the hospital. A well-matched one does better. And this year’s vaccine was updated across all three components to close that gap.
Current Clinical Guidelines
Who’s eligible?
If you are over 9 years of age and haven’t yet received a 2026-2027 flu vaccine, you’re eligible.
Children between 6 months and 8 years of age need one or two doses:
- 1 dose if 2 or more prior doses are documented before July 1, 2026
- 2 doses, administered at least 4 weeks apart, if 2 or more prior doses are not documented
A note on federal guidance this year: ACIP’s formal 2026-2027 influenza recommendations haven’t been published in the usual way, because the committee has been without a quorum since a March 2026 court ruling. The standing recommendation — annual vaccination for everyone 6 months and older — is not in dispute, and the AAP, AAFP, and other professional societies have published their own 2026-2027 guidance. In New York, state law now authorizes pharmacist vaccination independently of ACIP.
Still unsure whether you’re eligible? Chat with one of our vaccination experts.
What Flu Vaccines Are Available?
None of the 2026-2027 flu vaccines is preferred over the others for the general population. All are recommended for anyone who hasn’t yet had an updated immunization.
This season we’re carrying three:
- Fluzone — standard-dose inactivated, approved for 6 months and up. This is the workhorse, and the right choice for most people under 50.
- Fluzone High-Dose — roughly four times the antigen content of a standard dose, for adults 65 and older. More antigen means a stronger immune response, and slightly more likelihood you’ll feel it in your arm for a day.
- mFLUSIVA — the new mRNA option, for adults 50 and older. Egg-free and made without antibiotics or preservatives.
If you’re 65 or older, you now have a real choice to make
For years, the answer for this age group was simple: get the high-dose one. Now there are two enhanced options on our shelf, and they’re genuinely different.
Fluzone High-Dose is the known quantity. It’s been in use for well over a decade, with a long track record in exactly this population, and it’s what we’ve been recommending to our 65+ patients for years.
mFLUSIVA is new. Moderna’s trial data showed it generating stronger antibody responses than the high-dose flu vaccine in adults 65 and older, which is a meaningful result. The caveat we want you to hear from us rather than discover later: its approval for 65+ came through the FDA’s accelerated pathway, with a confirmatory study still running. Approval for ages 50 through 64 is standard, full approval.
Neither is a wrong answer. If you want the longest track record, take the high-dose. If you’re drawn to the stronger immune response data, or you’d prefer an egg-free product, mFLUSIVA is a reasonable pick. Come talk to us and we’ll walk through it.
If you’re 50 to 64
This is quietly the biggest change for our patients. Enhanced flu vaccines have historically been a 65-and-older thing, which left this age group with standard-dose only. mFLUSIVA is approved from 50 up, under standard approval, so there’s now an option here that didn’t exist before.
A note on egg
Our standard-dose and high-dose Fluzone products are egg-based. This isn’t a safety problem — egg allergy of any severity requires no additional precautions for flu vaccination, and hasn’t for several seasons now.
But if you’d simply prefer an egg-free vaccine, mFLUSIVA is our egg-free option this year, and it starts at 50. If you’re under 50 and want egg-free specifically, call us before you come in, and we’ll tell you honestly what we can and can’t do.
One clarification while we’re here
You may hear “high-dose” and “adjuvanted” used interchangeably. They’re not the same thing. Fluzone High-Dose gets a stronger response through more antigen; adjuvanted vaccines like Fluad get there by adding an immune-boosting compound. Both are legitimate enhanced options for 65+. We’re carrying the high-dose one this year, so if you’ve had Fluad elsewhere in the past, that’s what changed.
Call ahead if you want a specific product. Stock shifts through the season.
Learn More: Vaccines Do Work, But They’re Not Perfect
Our Recommendations
Who Should Definitely Get This Vaccine
We recommend everyone 6 months and older get vaccinated every flu season.
Children 6 months through 8 years may need 2 doses during a single season. Everyone else needs 1 dose per season.
Vaccination is particularly important for those at increased risk of severe illness and complications: older adults, immunocompromised individuals, people with chronic heart or lung conditions, and pregnant people.
We recommend that people who are pregnant, might become pregnant, or are up to two weeks postpartum during influenza season receive any licensed, age-appropriate IIV or RIV product. Vaccination can occur at any point during pregnancy, before or during the season — and it protects the baby during their first several months of life, before they’re old enough for their own dose.
People with minor illnesses, such as a cold, may be vaccinated. People who are moderately or severely ill should usually wait until they recover.
And the rule that beats every brand preference: the best flu vaccine is the one you actually get. If your preferred product isn’t available, take an appropriate alternative rather than delaying.
Who Should Not Get This Vaccine
- A history of severe allergic reaction to a vaccine component or following a prior dose is a contraindication to further doses.
- Moderate or severe acute illness, with or without fever, is a precaution — wait until you recover. Minor illness is fine.
- History of Guillain-Barré syndrome within 6 weeks of a previous influenza vaccine is a precaution for all flu vaccines licensed in the U.S.
- LAIV (the nasal spray) is contraindicated in pregnancy. IIV and RIV are recommended.
To reiterate on egg allergy: no additional safety measures are recommended, regardless of the severity of previous reactions. If you’d still prefer to avoid egg, mFLUSIVA is our egg-free option — see the note above about age.
The Best Time to Get The Flu VaccineThe Best Time to Get The Flu Vaccine
“Generally October or early November — but watch out for early flu surges.” — Dr. Neal Smoller
Flu season traditionally ramps up in late October or November, peaks between December and February, and runs until about May. But there are plenty of recorded examples of early starts — last season began early in multiple countries — so effective timing has to account for that.
The general target remains October or early November. If it looks like flu is arriving early, don’t wait for the calendar.
Learn More: Seasonal Vaccination: When Should You Get Your Vaccines in 2026?
Side Effects
“Local reactions are the most common adverse reactions following the flu shot. These include soreness, redness, tenderness, or swelling at the injection site. These reactions generally last only 1 to 2 days. In clinical trials, pain at the injection site was the most common side effect.” — Dr. Neal Smoller PharmD
Nonspecific systemic symptoms — fever, chills, malaise, muscle aches — occur less often and typically in first-time recipients. When they appear, it’s usually within 6 to 12 hours and lasts 1 to 2 days.
Febrile seizures in young children. In some seasons, IIV has been associated with a small increased risk of febrile seizures on the day of and day after vaccination in young children, more likely if given the same day as PCV13 and DTaP. Most febrile seizures are brief with a good prognosis. This was reviewed and did not change the recommendation — these vaccines can still be given on the same day.
Guillain-Barré syndrome. GBS is a serious neurological condition known to occur after various infections, particularly gastrointestinal and upper respiratory ones. Safety monitoring of seasonal IIV over many years has not detected a clear link. If there is a risk from IIV, it would be no more than 1 to 2 cases per million people vaccinated — and the risk of GBS after influenza illness appears higher than any potential risk from vaccination.
Learn more about the officially listed side effects of the flu vaccine here.
Are Flu Vaccines Effective?
In a well-matched season, flu vaccination reduces the risk of influenza illness by roughly 40% to 60% in the overall population.
Last season demonstrated the floor rather than the ceiling: against a drifted H3N2 strain, effectiveness against hospitalization and ED visits still ran 32-39% in adults and 72-75% in children. Not what we’d want, but far from nothing — and concentrated exactly where it matters most, on the outcomes that put people in a hospital bed.
Studies have demonstrated a range of benefits beyond simply not getting sick: fewer medical visits, fewer ICU and hospital admissions, shorter stays, and fewer deaths in children. Vaccinated people who do get sick tend to have milder illness. Flu vaccination has also been associated with lower rates of cardiac events among people with heart disease and reduced hospitalization risk in pregnancy.
Effectiveness depends on several factors: how closely vaccine strains match circulating ones, the age and health of the recipient, and the vaccine type. Duration of immunity is less than a year, because of both antibody waning and antigenic drift in circulating viruses. And the vaccine is generally less effective at preventing illness in adults 65 and older — which is precisely why enhanced formulations exist for that group.
Learn More: Vaccine Season Preview: 2026-2027
Flu Who? 2026-2027 Flu Vaccine Updates for the Win
Long story short: the updated 2026-2027 formulas have reached your area, or will shortly. Time to schedule.
This year’s vaccine got a full three-strain refresh after a season that hit harder than most. That’s the system working the way it’s supposed to — surveillance spots the drift, the composition gets updated, and the next vaccine aims at where the virus actually went.
Stay safe and healthy this cold and flu season with a science-backed vaccine, but don’t forget that vaccination is just one part of a wellness strategy. To learn more about scheduling your flu vaccine and other practices to keep you in tip-top shape, speak with one of our experts or keep exploring our blog.